Liquidia Corp (LQDA)

• Market cap: $976M
• 1 day: 0.79%
• 5 days: 1.77%
• 1 month: 2.49%
• 3 months: 13.93%
• 6 months: -8.49%
• Year to date: 0.00%
• 1 year: -0.77%
• 5 years: 227.56%
• 10 years: 3.87%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Employees: 145

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

89% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 19

17% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 7 (+1) [Q3]

13% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 45

12% more funds holding

Funds holding: 137 [Q2] → 154 (+17) [Q3]

1.74% more ownership

Funds ownership: 61.45% [Q2] → 63.18% (+1.74%) [Q3]

5% less call options, than puts

Call options by funds: $18.3M | Put options by funds: $19.3M

7% less capital invested

Capital invested by funds: $563M [Q2] → $526M (-$36.9M) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $19 65% upside
• Avg. target: $27 134% upside
• High target: $30 160% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target	152% upside $29	Buy Reiterated	14 Nov 2024
Needham Serge Belanger 37% 1-year accuracy 46 / 126 met price target	65% upside $19	Buy Reiterated	14 Nov 2024
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target	160% upside $30	Sector Outperform Initiated	16 Oct 2024
LifeSci Capital Cory Jubinville 100% 1-year accuracy 1 / 1 met price target	160% upside $30	Outperform Initiated	3 Oct 2024